| 摘要 |
In the present invention there is disclosed hydrobromide salt of 3-(N-methyl-2(R)pyrrolidinylmethyl)-5-(2-phenylsulfonylethyl)-1H-indole of the general formula I. This salt comprises crystalline {alpha}-polymorphous form exhibiting in Nujol suspension infrared spectrum containing significant absorption bands at {nu} = 3371, 3293, 2713, 2524, 1419, 1343, 1307, 1264, 1151, 1086, 1020, 1008, 999, 922, 900, 805, 758, 740, 728, 689, 672, 652, 640, 598, 581, 573, 531, 498, 465, 457, 443, 428, 422, 414 and 399 cme-1 and crystalline {beta}-polymorphous form containing in analogous spectrum significant absorption bands at {nu} = 3239, 2672, 2656, 2632, 1409, 1366, 1351, 1334, 1303, 1293, 1152, 1138, 1122, 1098, 1086, 791, 771, 746, 688, 634, 557, 528, 484, 476, 469, 463, 455, 432, 424, 413 and 401 cme-1. In the present invention there are also claimed a pharmaceutical preparation containing the above-indicated crystalline {alpha}-polymorphous form, the use of the {alpha}-polymorphous form for preparing a medicament for treating or prophylaxis of pathological states in which selective agonist of 5-HTi1 receptor is indicated. Such pathological state can be represented for instance by migraine. In the present invention there is further claimed a process for preparing the {alpha}-form of the compound of the general formula I.
|
